Research Progress Of HGF/c-MET Inhibitors In Advanced Non-small Cell Lung Cancer

Non-small cell lung cancer(NSCLC)is the main strategy in the treatment of platinum based chemotherapy,because of more adverse reactions,the current research directions of non-small cell lung cancer and more committed to maximize the survival rate of patients and improve the quality of their lives,especially in advanced NSCLC patients.Epidermal growth factor receptor inhibitor(EGFR-TKI)in the treatment of advanced NSCLC patients changes the inherent treatment model that based on platinum drugs especially in order to gefitinib and erlotinib as the representative of the first generation EGFR-TKI.EGF-TIKI has become the first choice for drug sensitive mutation positive patients that has already achieved great success in the past ten years.However,the resistance of EGFR-TKIs has be inevitable and gradually become the main obstacle of its effects.Therefore,most of the current studies on tumor targeting therapy is currently the main direction to find new targets and get overcome the drug resistance.Insight into the mechanisms of resistance to new development strategies or new drugs to overcome drug resistance and prolong the life of patients with non-small cell lung cancer has become the current focus of cancer research.Now,more and more evidence in the HGF/c-MET pathway in non-small cell lung cancer plays an important role in the development of met disorders,and the signal involving a variety of mechanisms,including met gene mutation,met amplification,met overexpression and met rearrangement.Above them,MET amplification and MET overexpress both are relative to the resistance of EGFR-TKIs.